140TiPAURA3 DESIGN: A RANDOMISED, PHASE III STUDY OF AZD9291 VERSUS SECOND-LINE CHEMOTHERAPY FOR PATIENTS (PTS) WITH EGFR-TKI-RESISTANT (T790M) ADVANCED NON-SMALL CELL LUNG CANCER


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles